Long-term efficacy and predictors of pembrolizumab-based regimens in patients with advanced esophageal cancer in the real world

doi:10.3748/wjg.v29.i41.5641

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 41

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4175)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-5) series.

Item

Count

PDF

WORD

HTML

1944

Figures (1-4)

263

Tables (1-5)

251

Sum=2583

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

186

Download

494

Sum=680

Publishing Process of This Article

Item

Count

Browse

190

Download

569

Sum=759

Nov 7, 2023 (publication date) through Feb 7, 2025

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Nov 7, 2023; 29(41): 5641-5656
Published online Nov 7, 2023. doi: 10.3748/wjg.v29.i41.5641

Table 4 Summary of disease-free survival

	Group B (n = 21)
Patients with event	7 (33.3%)
Patients without event	14 (66.7%)
Time to event (mo)
Median	-
95%CI	5.0, -
25% and 75%-ile	17.50, -
Min-max	2.6-27
12 mo probability (95%CI)	85.0 (60.4-94.9)
18 mo probability (95%CI)	75.0 (50.0-88.7)

Group B: Neoadjuvant therapy plus pembrolizumab. CI: Confidence interval.

Citation: Wang HC, Huang X, Chen J, Li Y, Cong Y, Qu BL, Feng SQ, Liu F. Long-term efficacy and predictors of pembrolizumab-based regimens in patients with advanced esophageal cancer in the real world. World J Gastroenterol 2023; 29(41): 5641-5656
URL: https://www.wjgnet.com/1007-9327/full/v29/i41/5641.htm
DOI: https://dx.doi.org/10.3748/wjg.v29.i41.5641